NEW YORK (GenomeWeb News) – Quest announced today a definitive agreement to sell its HemoCue business to Danaher's Radiometer Medical for about $300 million.

Separately, Fitch Ratings affirmed Quest Diagnostics' Issuer Default Rating at BBB+ after the close of the market on Friday.

Based in Cypress, Calif., HemoCue develops hemoglobin, glucose, and other point-of-care testing systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.